Mankind Pharma Ltd

Mankind Pharma Q2 2025 QIP Funds Fully Utilized 📊

- Monitoring Agency Report for Q2 2025 (ended June 30) prepared by CARE Ratings Limited.

- QIP issue proceeds totaled ₹3000 crore.

- No deviations from the objects of the issue were observed.

- ₹2900.03 crore used for repayment of Commercial Paper Series I.

- ₹55.00 crore allocated for General Corporate Purposes.

- ₹44.97 crore covered issue expenses, including ₹2.43 crore reimbursement to Bharat Serums and Vaccines Limited (BSV).

- All proceeds fully utilized with no unutilized amounts remaining.